Видео ютуба по тегу Imugene

Imugene’s azer-cel hits 82% response rate in 2025
Imugene’s azer-cel hits 82% response rate in 2025
Imugene trial: 75% response rate in diffuse large B-cell lymphoma
Imugene trial: 75% response rate in diffuse large B-cell lymphoma
Imugene (ASX:IMU): Конференция по инвестициям в драгоценные камни ASX, организованная Stock Network
Imugene (ASX:IMU): Конференция по инвестициям в драгоценные камни ASX, организованная Stock Network
Imugene (ASX: IMU)
Imugene (ASX: IMU)
IMUGENE DOSES FIRST PATIENT IN VAXINIA PHASE 1 TRIAL
IMUGENE DOSES FIRST PATIENT IN VAXINIA PHASE 1 TRIAL
ausbiz: Imugene transforms the cancer treatment landscape one trial at a time
ausbiz: Imugene transforms the cancer treatment landscape one trial at a time
Компания Imugene готовит ключевое исследование препарата Azer-Cel совместно с FDA
Компания Imugene готовит ключевое исследование препарата Azer-Cel совместно с FDA
Imugene gets FDA backing for azer-cel treatment
Imugene gets FDA backing for azer-cel treatment
Imugene's CAR-T therapy hits 82% response rate
Imugene's CAR-T therapy hits 82% response rate
Imugene, JW partner on CF33-CD19 for solid tumors
Imugene, JW partner on CF33-CD19 for solid tumors
The stock of the day is Imugene (IMU)
The stock of the day is Imugene (IMU)
Imugene Limited (ASX:IMU) presentation at Ausbiz Investor Connect October 2025
Imugene Limited (ASX:IMU) presentation at Ausbiz Investor Connect October 2025
Imugene (ASX:IMU) doses first patient in IV arm of Phase 1 onCARlytics trial targeting solid cancers
Imugene (ASX:IMU) doses first patient in IV arm of Phase 1 onCARlytics trial targeting solid cancers
Вебинар для инвесторов Imugene — результаты встречи FDA
Вебинар для инвесторов Imugene — результаты встречи FDA
Imugene progresses onCARlytics solid tumour trial to combination arm
Imugene progresses onCARlytics solid tumour trial to combination arm
'The Why' | Imugene, Developing Cancer Immunotherapies ASX: IMU
'The Why' | Imugene, Developing Cancer Immunotherapies ASX: IMU
Combination CAR T Oncolytic Virus Immunotherapy Kills Tumors
Combination CAR T Oncolytic Virus Immunotherapy Kills Tumors
Imugene @ AACR 2020: PD1-Vaxx (IMU-201) Phase 1 Briefing
Imugene @ AACR 2020: PD1-Vaxx (IMU-201) Phase 1 Briefing
Lymphoma Survivor Shares His Story: Breakthrough CAR-T Trial | Imugene on 7NEWS Australia
Lymphoma Survivor Shares His Story: Breakthrough CAR-T Trial | Imugene on 7NEWS Australia
To say something is giving you 81%, it's spectacular
To say something is giving you 81%, it's spectacular
Imugene Officially Announce Their HER-Vaxx Trial Results
Imugene Officially Announce Their HER-Vaxx Trial Results
Imugene HER-Vaxx video ASX: IMU | AN EMERGING LEADER IN CANCER IMMUNO-ONCOLOGY
Imugene HER-Vaxx video ASX: IMU | AN EMERGING LEADER IN CANCER IMMUNO-ONCOLOGY
Imugene’s Leslie Chong talks Azer-cel breakthrough
Imugene’s Leslie Chong talks Azer-cel breakthrough
7 News Australia | Australian company Imugene; saving lives using a cancer eating virus
7 News Australia | Australian company Imugene; saving lives using a cancer eating virus